Follow
Anusha Vallurupalli
Anusha Vallurupalli
Asst. Professor of Medicine, OHSU
Verified email at ohsu.edu - Homepage
Title
Cited by
Cited by
Year
Conn's Current Therapy 2023
RD Kellerman, DP Rakel
Elsevier Health Sciences, 2022
552022
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma
TJ Phillips, AJ Olszewski, J Munoz, TM Kim, DH Yoon, R Greil, J Westin, ...
BLOOD 136, 2020
442020
Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1
Z Xu, HHSK Potula, A Vallurupalli, D Perry, H Baker, BP Croker, ...
The Journal of Immunology 186 (12), 6673-6682, 2011
382011
Conn's current therapy 2019
RD Kellerman, D Rakel
Elsevier Health Sciences, 2018
34*2018
A New Zealand Black-derived locus suppresses chronic graft-versus-host disease and autoantibody production through nonlymphoid bone marrow-derived cells
Z Xu, A Vallurupalli, C Fuhrman, D Ostrov, L Morel
The Journal of Immunology 186 (7), 4130-4139, 2011
292011
Randomized Phase II/III Study of DA-EPOCH-R+/-Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701
JS Abramson, AS Ruppert, S Giri, A Hudson, ED Hsi, RF Little, SD Gore, ...
Blood 138, 523, 2021
212021
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells
PH Vekaria, A Kumar, D Subramaniam, N Dunavin, A Vallurupalli, ...
Leukemia 33 (7), 1675-1686, 2019
132019
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
GP Collins, TN Clevenger, KA Burke, B Yang, A MacDonald, ...
Leukemia & Lymphoma 62 (11), 2625-2636, 2021
52021
Fractionated dosing of CLR 131 in patients with relapsed or refractory multiple myeloma (RRMM)
S Ailawadhi, PJ Stiff, E Ibrahim, A Vallurupalli, EH Cull, DJ Green, K Oliver, ...
Blood 134, 144, 2019
42019
A Diverse Spectrum of Immune Complex–and Complement-Mediated Kidney Diseases Is Associated With Mantle Cell Lymphoma
NK Andeen, S Abdulameer, V Charu, JE Zuckerman, M Troxell, ...
Kidney international reports 7 (3), 568-579, 2022
32022
Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
T Banerjee, A Vallurupalli
Current Problems in Cancer 46 (1), 100825, 2022
32022
A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.
P Porcu, B Haverkos, E Brem, A Vallurupalli, T Feldman, O Alpdogan, ...
Journal of Clinical Oncology 37 (15_suppl), 7551-7551, 2019
32019
Functional characterization of NPM1-TYK2 fusion oncogene
BR 4. Kuravi S, Baker RW, Mushtaq MU, Saadi I, Lin TL, Vivian CJ ...
NPJ Precision Oncology 6 (1), 2022
22022
A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma
T Banerjee, M Newman, A Chen, RT Maziarz, L Schachter, SE Spurgeon, ...
Leukemia & Lymphoma, 1-4, 2023
12023
Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell …
U Greenbaum, H Hashmi, M Elsawy, S Kim, A Moskop, FT Awan, ...
Blood 140 (Supplement 1), 4636-4638, 2022
12022
ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL)
LE Budde, A Vallurupalli, S Babu, IS Lossos, JP Alderuccio, JC Chavez, ...
Hematological Oncology 37, 564-566, 2019
12019
CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas
S Kuravi, E Parrott, S Ganguly, A Vallurupalli, Y Saunthararajah, BS Blagg, ...
Blood 130, 2758, 2017
12017
Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell …
PR Geethakumari, K Wudhikarn, MD Jain, A Vallurupalli, S Kim, ...
Transplantation and Cellular Therapy, Official Publication of the American …, 2024
2024
Prolonged Cytopenias after Commercial CAR T-Cell Therapy with Tisagenlecleucel and Axicabtagene Ciloleucel for Relapsed and Refractory DLBCL.
G Manu, A Vallurupalli, S Williamson, J Brower, V Bachanova, JP McGuirk, ...
2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023
2023
Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R …
P Porcu, BM Haverkos, O Alpdogan, M Capra, TA Feldman, E Brem, ...
Blood 134, 465, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20